SCHEMBL20135322

SCHEMBL20135322

CCC1(c2ccc(C(=O)N3CCC(c4nc5ccc(C)nc5o4)CC3)cc2)NC(=O)NC1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.44
MAPT P10636 2/20 0.44
POLB P06746 1/20 0.43
THRB P10828 1/20 0.42
HTR2B P41595 1/20 0.42
ALDH1A1 P00352 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
ADAMTS5 Q9UNA0 2/20 0.39
ADAM17 P78536 1/20 0.38
CRBN Q96SW2 1/20 0.35
MEN1 O00255 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
RECQL P46063 1/20 0.35
KMT2A Q03164 1/20 0.35
TP53 P04637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20135319 1.00 LMNA (0.44) LMNAMAPTPOLBTHRBHTR2B
SCHEMBL20135177 0.85 LMNA (0.42) LMNAMAPTPOLBTHRBHTR2B
SCHEMBL20135178 0.85 LMNA (0.42) LMNAMAPTPOLBTHRBHTR2B
SCHEMBL20135702 0.78 TP53 (0.53) LMNAMAPTPOLBADAMTS5ADAM17
SCHEMBL20135700 0.78 TP53 (0.53) LMNAMAPTPOLBADAMTS5ADAM17
SCHEMBL20135507 0.77 UBE2M (0.55) LMNAMAPTTHRBALDH1A1MEN1
SCHEMBL20135503 0.77 UBE2M (0.55) LMNAMAPTTHRBALDH1A1MEN1
SCHEMBL29688756 0.77 TP53 (0.50) LMNAMAPTADAMTS5ADAM17CRBN
SCHEMBL20135505 0.77 TP53 (0.50) LMNAMAPTADAMTS5ADAM17CRBN
SCHEMBL20135508 0.77 TP53 (0.50) LMNAMAPTADAMTS5ADAM17CRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 LMNA 4264/4885MAPT 4505/4885POLB 1991/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 LMNA 4113/4885MAPT 4265/4885POLB 1970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.